Literature DB >> 32217780

Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea.

Juan F Masa1,2,3, Babak Mokhlesi4, Iván Benítez2,5, Francisco Javier Gómez de Terreros Caro6,2,3, M-Ángeles Sánchez-Quiroga2,3,7, Auxiliadora Romero2,8, Candela Caballero2,8, Maria Luz Alonso-Álvarez2,9, Estrella Ordax-Carbajo2,9, Teresa Gómez-García2,10, Mónica González11, Soledad López-Martín12, Jose M Marin2,13, Sergi Martí2,14, Trinidad Díaz-Cambriles2,15, Eusebi Chiner16, Carlos Egea12,17, Javier Barca3,18, Francisco-José Vázquez-Polo19, Miguel Angel Negrín19, María Martel-Escobar19, Ferran Barbé2,5, Jaime Corral-Peñafiel6,2,3.   

Abstract

BACKGROUND: Obesity hypoventilation syndrome (OHS) is treated with either non-invasive ventilation (NIV) or CPAP, but there are no long-term cost-effectiveness studies comparing the two treatment modalities.
OBJECTIVES: We performed a large, multicentre, randomised, open-label controlled study to determine the comparative long-term cost and effectiveness of NIV versus CPAP in patients with OHS with severe obstructive sleep apnoea (OSA) using hospitalisation days as the primary outcome measure.
METHODS: Hospital resource utilisation and within trial costs were evaluated against the difference in effectiveness based on the primary outcome (hospitalisation days/year, transformed and non-transformed in monetary term). Costs and effectiveness were estimated from a log-normal distribution using a Bayesian approach. A secondary analysis by adherence subgroups was performed.
RESULTS: In total, 363 patients were selected, 215 were randomised and 202 were available for the analysis. The median (IQR) follow-up was 3.01 (2.91-3.14) years for NIV group and 3.00 (2.92-3.17) years for CPAP. The mean (SD) Bayesian estimated hospital days was 2.13 (0.73) for CPAP and 1.89 (0.78) for NIV. The mean (SD) Bayesian estimated cost per patient/year in the NIV arm, excluding hospitalisation costs, was €2075.98 (91.6), which was higher than the cost in the CPAP arm of €1219.06 (52.3); mean difference €857.6 (105.5). CPAP was more cost-effective than NIV (99.5% probability) because longer hospital stay in the CPAP arm was compensated for by its lower costs. Similar findings were observed in the high and low adherence subgroups.
CONCLUSION: CPAP is more cost-effective than NIV; therefore, CPAP should be the preferred treatment for patients with OHS with severe OSA. TRIAL REGISTRATION NUMBER: NCT01405976. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  non invasive ventilation; sleep apnoea

Year:  2020        PMID: 32217780     DOI: 10.1136/thoraxjnl-2019-213622

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  CPAP titration failure is not equivalent to long-term CPAP treatment failure in patients with obesity hypoventilation syndrome: a case series.

Authors:  Alejandra C Lastra; Juan F Masa; Babak Mokhlesi
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

2.  Risk factors associated with pulmonary hypertension in obesity hypoventilation syndrome.

Authors:  Juan F Masa; Iván D Benítez; Shahrokh Javaheri; Maria Victoria Mogollon; Maria Á Sánchez-Quiroga; Francisco J Gomez de Terreros; Jaime Corral; Rocio Gallego; Auxiliadora Romero; Candela Caballero-Eraso; Estrella Ordax-Carbajo; María F Troncoso; Mónica González; Soledad López-Martín; José M Marin; Sergi Martí; Trinidad Díaz-Cambriles; Eusebi Chiner; Carlos Egea; Javier Barca; Ferrán Barbé; Babak Mokhlesi
Journal:  J Clin Sleep Med       Date:  2022-04-01       Impact factor: 4.062

3.  Results of CPAP Titration and Short-Term Adherence Rates in Patients with Obesity Hypoventilation Syndrome and Mild/Moderate Obstructive Sleep Apnea.

Authors:  Ahmed S BaHammam; Salih A Aleissi; Samar Z Nashwan; Awad H Olaish; Aljohara S Almeneessier
Journal:  Nat Sci Sleep       Date:  2022-06-15

4.  Long-Term Adherence to Positive Airway Pressure Therapy in Saudi Ambulatory Patients with Obesity Hypoventilation Syndrome and Severe Obstructive Sleep Apnea: A One-Year Follow-Up Prospective Observational Study.

Authors:  Aljohara S Almeneessier; Salih Aleissi; Awad H Olaish; Ahmed S BaHammam
Journal:  Nat Sci Sleep       Date:  2021-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.